Enliven Therapeutics, Inc. (ELVN)
17.70
-1.07
(-5.70%)
USD |
NASDAQ |
Dec 12, 12:48
Enliven Therapeutics EPS Diluted (Quarterly): -0.3245 for Sept. 30, 2025
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| CEL-SCI Corp. | -1.365 |
| AIM ImmunoTech, Inc. | -1.569 |
| IGC Pharma, Inc. | -0.0201 |
| NovaBay Pharmaceuticals, Inc. | -0.22 |
| Protalix Biotherapeutics, Inc. | 0.0291 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -20.15M |
| Total Expenses (Quarterly) | 20.15M |
| Enterprise Value | 636.77M |
| Earnings Yield | -10.43% |
| Normalized Earnings Yield | -10.43 |